Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
The Journal of Investigative Dermatology
|
December 10, 2021
Autoinflammation: Interferonopathies and Other Autoinflammatory Diseases
Sinisa Savic, James Coe, Philip Laws
Journal of Cutaneous Medicine and Surgery
|
September 15, 2016
A Case of Squamous Cell Carcinoma Developing Within a Red-Ink Tattoo
Sara Sherif, Elizabeth Blakeway, Chris Fenn, et al.
The British Journal of Dermatology
|
March 21, 2023
Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers
Lucy M Carter, Zoe Wigston, Philip Laws, et al.
Prehospital Emergency Care
|
May 27, 2011
No deaths associated with patient refusal of transport after naloxone-reversed opioid overdose
David A Wampler, D Kimberley Molina, John McManus, et al.
Dermatology and Therapy
|
April 21, 2026
Beyond the Skin: Assessing Itch in Atopic Dermatitis - Insights from UK Dermatologists. A Cross-Sectional Survey and Narrative Review
Philip Laws, Alberto Barea, Georgina Fremlin, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
February 26, 2021
Maintaining Clinical Freedom Whilst Achieving Value in Biologics Prescribing: An Integrated Cross-Specialty Consensus of UK Dermatologists, Rheumatologists and Gastroenterologists
Tim Raine, Maria Angeliki Gkini, Peter M Irving, et al.
Frontiers in Immunology
|
March 15, 2018
IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis
Charlie Bridgewood, Gareth W Fearnley, Anna Berekmeri, et al.
JAMA Dermatology
|
June 4, 2025
Adalimumab Monotherapy vs Adalimumab With Methotrexate for Psoriasis
Zenas Z N Yiu, Catherine H Smith, Philip Laws, et al.
JAMA Dermatology
|
July 6, 2022
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis
Zenas Z N Yiu, Gabrielle Becher, Brian Kirby, et al.
The British Journal of Dermatology
|
May 4, 2026
Serious infection risk with systemic treatments for psoriasis: A cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Heber Rew Bright Bright, Catherine H Smith, Philip Laws, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
The Journal of Investigative Dermatology
|
December 10, 2021
Autoinflammation: Interferonopathies and Other Autoinflammatory Diseases
Sinisa Savic, James Coe, Philip Laws
Journal of Cutaneous Medicine and Surgery
|
September 15, 2016
A Case of Squamous Cell Carcinoma Developing Within a Red-Ink Tattoo
Sara Sherif, Elizabeth Blakeway, Chris Fenn, et al.
The British Journal of Dermatology
|
March 21, 2023
Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers
Lucy M Carter, Zoe Wigston, Philip Laws, et al.
Prehospital Emergency Care
|
May 27, 2011
No deaths associated with patient refusal of transport after naloxone-reversed opioid overdose
David A Wampler, D Kimberley Molina, John McManus, et al.
Dermatology and Therapy
|
April 21, 2026
Beyond the Skin: Assessing Itch in Atopic Dermatitis - Insights from UK Dermatologists. A Cross-Sectional Survey and Narrative Review
Philip Laws, Alberto Barea, Georgina Fremlin, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
February 26, 2021
Maintaining Clinical Freedom Whilst Achieving Value in Biologics Prescribing: An Integrated Cross-Specialty Consensus of UK Dermatologists, Rheumatologists and Gastroenterologists
Tim Raine, Maria Angeliki Gkini, Peter M Irving, et al.
Frontiers in Immunology
|
March 15, 2018
IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis
Charlie Bridgewood, Gareth W Fearnley, Anna Berekmeri, et al.
JAMA Dermatology
|
June 4, 2025
Adalimumab Monotherapy vs Adalimumab With Methotrexate for Psoriasis
Zenas Z N Yiu, Catherine H Smith, Philip Laws, et al.
JAMA Dermatology
|
July 6, 2022
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis
Zenas Z N Yiu, Gabrielle Becher, Brian Kirby, et al.
The British Journal of Dermatology
|
May 4, 2026
Serious infection risk with systemic treatments for psoriasis: A cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Heber Rew Bright Bright, Catherine H Smith, Philip Laws, et al.
Page
of 2